Nitric oxide stimulates human sperm motility via activation of the cyclic GMP/protein kinase G signaling pathway

Erica Miraglia¹, Federico De Angelis², Elena Gazzano¹, Hossain Hassanpour³, Angela Bertagna⁴, Elisabetta Aldieri¹, Alberto Revelli² and Dario Ghigo¹

¹Department of Genetics, Biology and Biochemistry, University of Torino, Via Santena, 5/bis, 10126 Torino, Italy, ²Reproductive Medicine and IVF Unit, Department of Obstetrical and Gynecological Sciences, S. Anna Hospital, University of Torino, 10126 Torino, Italy, ³Department of Basic Sciences, College of Veterinary Medicine, University of Shahrekord, Shahrekord 88186 34141, Iran and ⁴Department of Internal Medicine, University of Torino, S. Giovanni Battista Hospital, 10126 Torino, Italy

Correspondence should be addressed to D Ghigo; Email: dario.ghigo@unito.it

Abstract

Nitric oxide (NO), a modulator of several physiological processes, is involved in different human sperm functions. We have investigated whether NO may stimulate the motility of human spermatozoa via activation of the soluble guanylate cyclase (sGC)/cGMP pathway. Sperm samples obtained by masturbation from 70 normozoospermic patients were processed by the swim-up technique. The kinetic parameters of the motile sperm-rich fractions were assessed by computer-assisted sperm analysis. After a 30–90 min incubation, the NO donor S-nitrosoglutathione (GSNO) exerted a significant enhancing effect on progressive motility (77, 78, and 78% vs 66, 65, and 62% of the control at the corresponding time), straight linear velocity (44, 49, and 48 m/s vs 34, 35, and 35.5 m/s), curvilinear velocity (81, 83, and 84 m/s vs 68 m/s), and average path velocity (52, 57, and 54 m/s vs 40, 42, and 42 m/s) at 5 μM but not at lower concentrations, and in parallel increased the synthesis of cGMP. A similar effect was obtained with the NO donor spermine NONOate after 30 and 60 min. The GSNO-induced effects on sperm motility were abolished by 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (a specific sGC inhibitor) and mimicked by 8-bromo-cGMP (8-Br-cGMP; a cell-permeating cGMP analog); the treatment with Rp-8-Br-cGMPS (an inhibitor of cGMP-dependent protein kinases) prevented both the GSNO- and the 8-Br-cGMP-induced responses. On the contrary, we did not observe any effect of the cGMP/PRKG1 (PKG) pathway modulators on the onset of hyperactivated sperm motility. Our results suggest that NO stimulates human sperm motility via the activation of sGC, the subsequent synthesis of cGMP, and the activation of cGMP-dependent protein kinases.

Reproduction (2011) 141 47–54

Introduction

Nitric oxide (NO) is a free radical gas, which participates as a mediator in several physiopathological events, such as regulation of vascular tone, neurotransmission, apoptosis, and inflammation (Wink & Mitchell 1998). NO is synthesized by NO synthases (NOS), a family of enzymes catalyzing the conversion of L-arginine to L-citrulline and NO with a 1:1 stoichiometry (Nathan & Xie 1994). Three NOS isoforms have been described: endothelial (eNOS, NOS3), neuronal (nNOS, NOS1), and inducible (iNOS or NOS2; Nathan & Xie 1994). NO has been demonstrated to play a role in a variety of functions in the human reproductive tract, including sperm motility (Lewis et al. 1996), chemotaxis (Miraglia et al. 2007), and sperm–zona pellucida binding ability (Sengoku et al. 1998). NOS isoforms have been localized in the acrosome and tail of human, mouse, and bovine spermatozoa (Herrero et al. 1996, Meiser & Schulz 2003), and low motility spermatozoa have been shown to exhibit aberrant patterns of NOS3 immunostaining (O’Bryan et al. 1998). It has been reported that low concentrations of NO (25–100 nM sodium nitroprusside) enhance the motility of human spermatozoa (Hellstrom et al. 1994, Zhang & Zheng 1996). Accordingly, human sperm motility is inhibited by the NOS inhibitor N⁴-nitro-ω-arginine methyl ester and by the NO scavenger methylene blue (Lewis et al. 1996, Donnelly et al. 1997). On the other hand, high NO concentrations (25–125 μM pure NO, 0.25–2.5 mM sodium nitroprusside, 12–600 μM S-nitroso-N-acetylpenicillamine, and 100–125 μM 3-morpholinosydnonimine) seem to exert opposite effects on the motility of human spermatozoa in vitro (Rosselli et al. 1995, Weinberg et al. 1995, Nobunaga et al. 1996). Studies on sperm capacitation showed that NO (1–100 μM spermine NONOate...
(SPNO) or diethylamine-NONOate) increases cAMP levels, thus triggering protein kinase A activation and tyrosine phosphorylation (Herrero et al. 2000) and is also involved in activation of protein ERKs (Thundathil et al. 2003, O’Flaherty et al. 2006). On the other hand, like in many other cell types, NO activates the soluble guanylate cyclase (sGC) in human spermatozoa (Revelli et al. 2002). The NO donors sodium nitroprusside and SPNO have been shown to increase the intracellular levels of cGMP in human (Zhang & Zheng 1996, Revelli et al. 2001) and murine (Herrero et al. 1998) spermatozoa respectively, and recently the sGC has been identified in human sperm by immunoblotting (Willipinski-Stapelfeldt et al. 2004). Although its levels in human sperm are about 100-fold lower than the cAMP spermatozoa respectively, and recently the sGC has been identified in human sperm by immunoblotting (Willipinski-Stapelfeldt et al. 2004). Although its levels in human sperm are about 100-fold lower than the cAMP content (Willipinski-Stapelfeldt et al. 2004), cGMP has been implicated in several sperm signaling pathways functions, such as capacitation, acrosome reaction, chemotaxis, and sperm–egg interaction (Revelli et al. 2001, 2002, Herrero et al. 2003, Miraglia et al. 2007). cGMP is thought to modulate also sperm motility. Indeed, the cGMP-dependent phosphodiesterase (PDE) inhibitor sildenafil was reported by some authors (Lefievre et al. 2000, Cuadra et al. 2000), but not by others (Andrade et al. 2000, Aversa et al. 2000, Burger et al. 2000), to increase the velocity and amplitude of lateral head displacement in human spermatozoa. Lefievre et al. (2000) observed an inhibition of sperm PDE activity with sildenafil at high concentrations, inhibiting many PDE and causing also an increase in cAMP, whereas Cuadra et al. (2000) reported that sildenafil stimulates sperm motility at much lower concentrations, quite close to the IC_{50} of sildenafil for the cGMP-dependent PDE. A recent review of ex vivo studies suggests that sildenafil and tadalafil exert a dose-dependent effect on sperm motility, which is enhanced at low doses but may be reduced at high concentrations, but further investigations are required to evaluate the mechanisms by which these PDE selective inhibitors modulate sperm motility (Dimitriadis et al. 2008).

Until now no clear data show a direct relationship between exposure to NO, increase of sperm cGMP levels, and changes of human sperm motility. Therefore, the aim of this study is to investigate whether human sperm motility, which is considered one of the most significant fertility-related sperm features (Hirano et al. 2001), is affected by NO via activation of the sGC/cGMP signaling pathway.

### Results

Since the swim-up procedure was performed in sperm washing medium (SWM) containing bicarbonate and albumin, as previously described (Miraglia et al. 2010), for a time sufficient to induce capacitation in most sperm cells, the experiments shown in each point of this paper can be considered as performed on capacitated spermatozoa (see also Materials and Methods section). Preliminary experiments of dose dependence were performed to establish the concentration of the NO donor S-nitrosoglutathione (GSNO) that affects human sperm motility patterns. A progressively motile sperm swims forward in an essentially straight line: rapid progressive motility (A) indicates sperm swimming with a progression velocity >25 μm/s, while slow progressive motility (B) indicates sperm swimming with a progression velocity = 5–25 μm/s (Krause & Viethen 1999). At the concentration of 5 μM, GSNO exerted a significant enhancing effect on progressive motility (A+B motility classes) at each time period considered, while at 0.1–1 μM it was not effective (Fig. 1A). When the spermatozoa were incubated with 10 μM GSNO, progressive motility (A+B classes) was comparable to that of untreated sperm (Fig. 1A). To check how long the effect of 5 μM GSNO takes to develop, time-dependence experiments were performed. The increase in sperm motility induced by GSNO was not significant at 10 and 20 μM GSNO. All data are presented as means ± S.E.M. (n=4).

**Figure 1** Effect of GSNO on sperm motility patterns. (A) The percentage of spermatozoa exhibiting a forward progressive motility (A+B WHO classes) were recorded by computer-assisted sperm analysis (CASA) after a 30 min (white bars), 60 min (black bars), or 90 min (hatched bars) incubation of 20 × 10^6 cells/200 μl with 0.1–10 μM S-nitrosoglutathione (GSNO). All data are presented as means ± S.E.M. (n=25). Significance versus control at the corresponding incubation time: *P<0.05. (B) The percentage of spermatozoa exhibiting a forward progressive motility (A+B WHO classes) were recorded by CASA after a 10, 20, 30, 60, or 90 min incubation of 20 × 10^6 spermatozoa/200 μl with 5 μM GSNO. All data are presented as means ± S.E.M. (n=4). Significance versus control (CTRL): *P<0.05.
20 min, but only after an at least 30 min incubation (Fig. 1B). By analyzing each class of motility, we have observed that the increase in progressive motility (WHO classes A+B) after treatment with GSNO was mainly due to a significant rise in the percentage of A class spermatozoa, which was counterbalanced by a parallel decrease in both C and D class spermatozoa; the amount of spermatozoa exhibiting a B pattern of motility did not change under all the experimental conditions (data not shown). On the contrary, the motion parameters linearity (LIN) and straightness (STR) were unaffected, and no induction of HA was observed (data not shown).

In the same way, GSNO strongly increased the individual parameters of sperm movement straight linear velocity (VSL), curvilinear velocity (VCL), and average path velocity (VAP) when added at 5 μM but not at 0.1–1 μM (data not shown). After the incubation with 10 μM GSNO, VSL, VCL, and VAP were comparable to those of untreated sperm, thus suggesting that GSNO at this concentration was not yet toxic, but it neither could improve the sperm motility (data not shown). SPNO is a faster NO donor than GSNO, when incubated with several samples (n=6) of spermatozoa, SPNO 0.5 μM significantly increased the progressive motility (A+B classes) after 30 (71.2±2 vs 51±1% in controls) and 60 min (69±3 vs 50±2% in controls). In the same experimental conditions, 0.5 μM SPNO also increased significantly VSL, VCL, and VAP (data not shown).

Oxidized glutathione (GSSG), the product of GSNO decomposition, is a powerful chelator of copper ions (Singh et al. 1999). Since copper ions can influence the release of NO from GSNO, we performed further experiments to check whether the increased sperm motility that we observed after incubation with GSNO is due to the chelation of copper by GSSG. We measured sperm motility in the presence of 5 μM reduced glutathione (GSH) or GSSG, to exclude that glutathione per se, in any form, could alter the progressive motility; both GSH and GSSG had no significant effect on sperm motility (n=4; data not shown). To chelate the copper, we also performed other experiments with 1 mM EDTA, and even in this case we did not observe any significant modification versus controls and versus GSNO alone (n=4; data not shown). After EDTA treatment the level of calcium was about 1 mM.

Thereafter, the 5 μM concentration of GSNO was chosen to perform the subsequent experiments. The NO donor induced a significant increase in sperm progressive motility measured by computer-assisted sperm analysis (CASA) after incubation with freshly ejaculated human samples for 30, 60, and 90 min (Fig. 1B). The sGC inhibitor 1H-[1,2,4]oxadiazolo-[4,3-a]quinoxalin-1-one (ODQ) did not affect the progressive motility when added alone, but completely blunted its GSNO-elicited increase at each time period (Fig. 2). On the other hand, 8-bromo-cGMP (8-Br-cGMP), a cell-permeating cGMP analog, exerted a significant enhancing effect on progressive motility per se and completely reversed the inhibitory effect of ODQ on the GSNO-stimulated increase (Fig. 2). Finally, the PRKG1 inhibitor Rp-8-Br-cGMPS, which per se did not modify the sperm progressive motility, abolished the effects of GSNO and 8-Br-cGMP on this motion parameter (Fig. 2).

In order to confirm the role of NO in this process, we also measured the progressive motility in the presence of the NO scavenger PTIO. In all, 100 μM 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxide (PTIO) did not affect sperm motility when used alone, but when co-incubated with GSNO (5 μM) it completely reversed the increase in motility induced by GSNO (Fig. 3). In the presence of 20 μl packed fresh red blood cells, used as reservoirs for the NO scavenger oxyhemoglobin, the motility results were the same observed with PTIO (n=3; data not shown). To this purpose, we incubated the spermatozoa at the reported concentrations used in the other experiments and for the indicated times (30, 60, and 90 min) in the lower compartment of a transwell system (having a polycarbonate transwell insert membrane with pore sizes of 3 μm, in 24-well plates provided by Corning Incorporated, Apton, MA, USA), the upper compartment containing 20 μl packed fresh red blood cells in 0.5 ml SWM. After each incubation time, the upper compartment was taken out and the sperm motility parameters were measured as described in ‘Materials and Methods’ section.

We also evaluated the effect of NO on sperm kinetic parameters assessed by CASA. In the presence of GSNO, the VSL markedly increased, an effect that was abolished by ODQ (which per se did not modify this motion parameter), as shown in Fig. 4A; the cGMP analog...
8-Br-cGMP significantly stimulated VSL, and bypassed the inhibition exerted by ODQ on the GSNO-evoked VSL increase (Fig. 4A). The co-incubation with Rp-8-Br-cGMPS completely blunted the positive action of both GSNO and 8-Br-cGMP on VSL (Fig. 4A).

The same pattern of response was observed when considering the VCL (Fig. 4B) and the VAP (Fig. 4C) of human spermatozoa treated under the same experimental conditions.

Finally, under the same experimental conditions, GSNO significantly increased the synthesis of cGMP in human spermatozoa at each incubation time considered; the absence of a significant time dependence suggests that GSNO exerts a maximal effect already after 30 min, and that between 30 and 90 min the synthesis of cGMP is maintained in a steady-state condition. The effect of GSNO was completely abolished by ODQ: as expected, after incubation with 8-Br-cGMP, both alone and together with GSNO and ODQ, the cGMP intracellular level was significantly higher than the control level (Fig. 5). Moreover, in this case, no time dependence was observed, suggesting that in our experimental conditions, the entry of 8-Br-cGMP into the cells and its degradation were balanced throughout the time of investigation.

Since the measurement of intracellular cGMP was performed in the presence of the PDE inhibitor 3-isobutyl-1-methylxanthine (IBMX) to inhibit cGMP hydrolysis, we performed further motility experiments on samples pretreated for 20 min with 200 µM IBMX and then for 30, 60, and 90 min with 5 µM GSNO. We observed that the pretreatment with IBMX did not influence the enhancement of sperm motility induced by NO (Fig. 3).

**Discussion**

The NO/cGMP signaling pathway modulates several physiopathological events of the mammalian reproductive tract (Rosselli et al. 1998). As far as sperm functions are concerned, NO released by sodium nitroprusside has been shown to play an important role in mouse sperm hyperactivation (HA; Herrero et al. 1994) and in...
In the 'Materials and Methods' section. The measurements were performed then, intracellular cGMP concentration was determined as described co-incubation: 5 μM GSNO, 10 μM ODQ, and 500 μM 8-Br-cGMP. Then, intracellular cGMP concentration was determined as described in 'Materials and Methods' section. The measurements were performed in triplicate, and data are presented as means ± S.E.M. (n=5). Significance versus CTRL: *P<0.01; versus GSNO: †P<0.005; versus GSNO + ODQ: ‡P<0.001.

the percentage of in situ motile (C class) and immotile (D class) cells. In parallel, the NO donor stimulated the sperm kinetic parameters assessed by CASA, VSL, VCL, and VAP. This is in accordance with a previous study reporting that sodium nitroprusside increased human sperm motility (Zhang & Zheng 1996). Such effect was detectable at 25–100 nM but not at 200–400 nM, whereas we observed a significant motility enhancement using 5 μM GSNO. This difference may be due to the different NO donor used and the different experimental procedure used to measure sperm motility. Indeed, that study evaluated a transmembrane migration ratio (the proportion of human spermatozoa moving across a membrane separating two chambers; Zhang & Zheng 1996), whereas CASA calculates the percentage of cells exhibiting a forward progressive motility and the kinetic parameters of each cell.

Compared with GSNO (having a half-life of hours, ranging from 10 to 38 h; Nikitovic & Holmgren 1996, Mancuso et al. 2003), SPNO is a faster NO donor, with a half-life of 39 min at 37 °C and pH 7.4 (Keofer et al. 1996). In further experiments using SPNO as NO donor, we observed that also the incubation with SPNO (0.5 μM) significantly increased the progressive motility (A+B classes), VSL, VCL, and VAP after 30 and 60 min.

In a previous work, we have demonstrated that GSNO and 8-Br-cGMP exerted a significant chemotactic effect on human spermatozoa without affecting their motion parameters (Miraglia et al. 2007). In that study, both substances were used at different concentrations and time periods compared with those used in this investigation. GSNO exerted a chemoattractant effect at 100 nM, while in this study it was ineffective on motility even at 1 μM. On the other hand, 8-Br-cGMP was used in the previous study at a 1 mM concentration, twofold higher than the one used in the present work. Moreover, in our previous work, we investigated the sperm motion parameters only after 20 min of incubation with GSNO and 8-Br-cGMP, whereas in the present work we used longer (30–90 min) time periods of observation (Miraglia et al. 2007). Since the intracellular levels of cGMP measured after incubation with either GSNO or 8-Br-cGMP were respectively similar in both the experimental works, in spite of the different incubation times and concentrations used, it is likely that these compounds exert a significant effect on sperm motility only when the level of intracellular cGMP is maintained increased for a time longer than the one necessary for cGMP to modulate chemotaxis. This suggestion may make sense, since it is reasonable to assume that at first time sperm needs to be simply oriented versus a source of NO and only subsequently, when the increase in cGMP shows to be persistently high, the motility should increase. The effect of GSNO on sperm motility is indeed mediated by an increased synthesis of cGMP, as the sGC inhibitor ODQ blunted the GSNO-elicited motility and abolished the increase in intracellular cGMP induced by

![Figure 5 Intracellular cGMP levels in human spermatozoa treated with agents modulating the cGMP pathway. Sperm samples (15×10⁶ cells/500 μl) were pretreated with 200 μM IBMX for 20 min, and subsequently they were incubated for 30, 60, or 90 min in the absence (CTRL) or presence of the following substances, alone or in co-incubation: 5 μM GSNO, 10 μM ODQ, and 500 μM 8-Br-cGMP.](image-url)
GSNO. The treatment with the cell-permeating cGMP analog 8-Br-cGMP, which augmented by nearly fourfold the intracellular content of cyclic nucleotide, strongly increased the forward progressive motility and the kinetic parameters VSL, VCL, and VAP. Moreover, 8-Br-cGMP reversed the inhibitory effect of ODQ on the GSNO-evoked increase in progressive motility and velocity, confirming that ODQ inhibited sperm motility by lowering the intracellular level of cGMP.

Taken together, these findings suggest that NO stimulates human sperm motility via the activation of sGC and the subsequent synthesis of cGMP. One of the main targets of cGMP in many tissues is a family of serine/threonine kinases, the PRKG1s (Hofmann 2005). Rp-8-Br-cGMPS, a PRKG1 inhibitor (Kawada et al. 1997), abolished the positive effect exerted by both GSNO and 8-Br-cGMP on sperm motility, suggesting that the effect of endogenous or exogenous cGMP on sperm movement is mediated by PRKG1 activity. Thus, from our data, PRKG1 seems to play a role in mediating not only the NO-elicited chemotaxis and the acrosome reaction (Revelli et al. 2001, Miraglia et al. 2007), but also in modulating several sperm motion patterns. On the other hand, we did not observe any effect of the cGMP/PRKG1 pathway modulators on the onset of hyperactivated sperm motility.

It is widely acknowledged that spermatozoa in the human female reproductive tract have close and prolonged contact with a significant array of NO-producing cells (Rosselli et al. 1998, Sun et al. 2005, Machado-Oliveira et al. 2008); the exact sites of NO production in the female genital tract remain to be investigated, but Machado-Oliveira et al. (2008) showed that detectable amounts of NO are produced in human cumulus fragments and oviduct explants. This free radical is relatively unreactive, and is able to diffuse from the cell in which it is generated to the neighbor cells, covering long distances in a very short time (Kröncke et al. 1997). Moreover, spermatozoa themselves produce and release NO during their trip along the upper female genital tract. This suggests that a complex interaction between spermatozoa, granulosa cells, and other cells of the female reproductive tract may submit human sperm to the amounts of NO that are sufficient to elicit in vivo changes of motility we have observed in vitro.

It is generally accepted that good sperm motility is a major component of normal male fertility. Men with poorly motile or immotile sperm are typically infertile or sterile (Turner 2006). A deeper knowledge of the role of the NO/cGMP/PRKG1 signaling pathway in the physiopathology of sperm motility could help to pharmacologically improve the fertilization capacity of human sperm or, alternatively, could lead to the development of an effective and safe male contraceptive based on sperm motility impairment.

Materials and Methods

Reagents

SWM was supplied by Celbio (Milan, Italy). It is based on the modified human tubal fluid (Quinn et al. 1985), containing sodium bicarbonate (4 mM), HEPES buffer (21 mM), human serum albumin (5 mg/ml). GSNO, ODQ, 8-Br-cGMP, and IBMX were purchased from Sigma Chemical Co. The inhibitor of cGMP-dependent protein kinases (PRKG1s), 8-bromoguanosine-3’,5’-monophosphorothioate Rp-isomer (Rp-8-Br-cGMPS), was from Biolog Life Science Institute (Bremen, Germany). The [3H]cGMP RIA kit was obtained from Amersham International.

Collection and preparation of sperm samples

Sperm samples were obtained by masturbation after 3–5 days of sexual abstinence from 70 normozoospermic patients belonging to couples presenting for infertility evaluation. Each donor gave informed consent allowing the use of his semen for our experiments. Institutional review board approval was obtained from the internal ethical committee that authorized the use of semen samples submitted to semen examination for experimental purposes. All samples were allowed to liquefy for at least 30 min at 37 °C, and then they were evaluated for sperm concentration, motility, and morphology according to the World Health Organization guidelines (World Health Organization 2001). Only specimens with normal parameters (concentration >20×10^6 spermatozoa/ml, progressive motility >50%) were used in the experiments.

Motile spermatozoa were capacitated by the swim-up technique (37 °C for 75 min in a 5% CO_2 atmosphere) using SWM as previously described (Miraglia et al. 2010). The presence of round cells was initially below 1×10^6 in all sperm samples, and was minimal if not absent after the swim-up technique in the final suspension. After swim-up, the motile sperm-rich fraction was centrifuged at 600 g for 10 min, the supernatant was discarded, and the pellets were re-suspended in SWM. The concentration of the spermatozoa suspensions was assessed in a Makler counting chamber (Sefi Medical Instruments, Haifa, Israel) under a phase-contrast microscope (magnification ×20), and adjusted to ~100×10^6 cells/ml. The dose-dependent effect of GSNO on sperm motility was investigated in the first 25 samples (20×10^6 cells/200 μl), the effect of the modulation of the cGMP pathway on sperm kinetic parameters was studied in the subsequent 40 samples (20×10^6 cells/200 μl), and finally the ability of the cGMP-modulating agents to modify the intracellular cGMP content was checked in the last 5 samples (15×10^6 cells/500 μl). GSNO was not toxic at the concentrations used, as checked by the eosin Y exclusion test (Cincik et al. 2007).

Analysis of motility parameters

Aliquots of sperm suspension (200 μl) in SWM, each containing 20×10^6 cells, were incubated under the experimental conditions indicated in section ‘Results’. Sperm motility parameters were assessed by CASA.
(CGA-WLJY-9000; CGA Distribution, Florence, Italy) after 30, 60, and 90 min of incubation. The following kinetic parameters were measured: percentage of spermatozoa exhibiting a forward progressive motility (A+B WHO classes), in situ motility (C WHO class), or no motility (D WHO class); VSL (which represents the average velocity, expressed in μm/s, measured from the beginning to the end of a linear track); VCL (which is the average velocity measured over the actual point-to-point track followed by the cell, expressed as μm/s); VAP (corresponding to the average velocity of smoothed cell’s pathway, expressed in μm/s); LIN = (VSL/VCL) × 100; STR (the percentage of correspondence of the cell’s pathway to a straight line, with 100% corresponding to the maximal extent of STR; Mortimer 1997). Sperm HA was also considered, using the following parameters: VCL ≥ 70 μm/s, ALH ≥ 7 μm, LIN ≤ 30%, and VSL ≤ 30 μm/s (Green & Fishel 1999).

**Measurement of intracellular cGMP**

The level of intracellular cGMP was measured as previously described (Miraglia et al. 2007). Briefly, aliquots of sperm suspensions (500 μl), each containing 15 × 10⁶ cells, were pre-treated for 20 min with the PDE inhibitor IBMX (200 μM) to inhibit cGMP hydrolysis, and then were co-incubated for 30, 60, or 90 min with the same substances (GSNO, ODQ, and 8-Br-cGMP) used for the assessment of motility parameters, alone or differently combined. Subsequently, the samples were centrifuged at 13 000 rpm for 3 min, 350 μl supernatant were tested by the cell, expressed as μm/s); VAP (corresponding to the average velocity of smoothed cell’s pathway, expressed in μm/s); LIN = (VSL/VCL) × 100; STR (the percentage of correspondence of the cell’s pathway to a straight line, with 100% corresponding to the maximal extent of STR; Mortimer 1997). Sperm HA was also considered, using the following parameters: VCL ≥ 70 μm/s, ALH ≥ 7 μm, LIN ≤ 30%, and VSL ≤ 30 μm/s (Green & Fishel 1999).

**Statistical analysis**

All data are provided as means ± S.E.M. The results were analyzed by a one-way ANOVA and Tukey’s and Bonferroni’s test (software: SPSS 11.0 for Windows; SPSS, Inc., Chicago, IL, USA), including the different times of incubation in the global significance evaluation. A P value < 0.05 was considered significant.

**Declaration of interest**

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

**Funding**

This research was supported by grants from Regione Piemonte (Ricerca Sanitaria Finalizzata) and Ministero dell’Istruzione, dell’Università e della Ricerca, Italy.

www.reproduction-online.org

**References**


Received 22 March 2010
First decision 15 April 2010
Revised manuscript received 22 September 2010
Accepted 20 October 2010